$2.30
-0.12-4.96%
Last update: Nov 9, 7:22 PM
Kalaris Therapeutics Inc
KLRSNASDAQ
The average analyst price target for Kalaris Therapeutics is $19.60, 750.6% above the current price. Of 7 analysts, 7 rate it Buy. Targets range from $14 to $25. The latest change came on Jun 15, 2026, when TD Cowen initiated coverage of Kalaris Therapeutics with a Buy rating.
Price Target Range — 3 Quarters
Analyst Consensus — 7 Analysts
Rating Trend — Last 9 Months
